Key result
Ruxolitinib improved overall response at week 24 and failure-free survival compared to investigator's choice for chronic GVHD, despite 61 patients crossing over to the ruxolitinib group.
Why the study?
Does ruxolitinib improve overall response at week 24 in patients with chronic GVHD compared to investigator choice therapy?
Does ruxolitinib improve overall response at week 24 in patients with chronic GVHD compared to investigator choice therapy?
Answers are grounded in this paper and cite their sources.
Ruxolitinib provides consistent benefits in overall response and symptoms for chronic GVHD compared to standard investigator-choice therapies.
The authors reply: Gratwohl observed that survival did not differ substantially between the trial groups at 6 months.Long-term survival will be reported when longer follow-up is available.However, we note that the trial was not powered to detect differences in overall survival and that the probability of survival may have been influenced by rescue therapies and crossover to ruxolitinib, which occurred in 61 patients at primary analysis and is likely to influence results from longer follow-up.Nevertheless, we do not believe that treatments must improve survival to be beneficial in this chronic disease.The open-label design that Gratwohl criticizes was unavoidable because no standard comparator is available.Instead, the control group received therapy for chronic GVHD according to investigator choice from 10 treatment options.Given the lack of standard practice in the field, the treatment that the patient would have received in clinical practice was considered the best comparator.Lastly, we note that the primary end point of this trial was overall response at week 24, which was checked for accuracy against National Institutes of Health response criteria.Key secondary end points were patient-reported symptoms and failure-free survival, which were improved in the ruxolitinib group.We agree that because this was not a blinded trial, clinician assessments, patient symptoms, and decisions about changing therapies may have been affected by the open-label design, but the consistency and magnitude of results from different perspectives, all in favor of ruxolitinib, give great confidence in the robustness of the results.Shibusawa summarizes South American and U.S. data about the association of socioeconomic status with survival and patient-reported symptoms of chronic GVHD.We did not collect information on income, ability to work, or having a partner to address whether these factors were associated with response, but randomization and adjustment for baseline symptom burden should have minimized substantial imbalances between the trial groups.
No takes yet. Share an insight, caveat, or question.
A 2021 study conducted a letter in Chronic GVHD. Ruxolitinib vs. Investigator choice from 10 treatment options was evaluated on Overall response at week 24. Ruxolitinib improved overall response at week 24 and failure-free survival compared to investigator's choice for chronic GVHD, despite 61 patients crossing over to the ruxolitinib group.
Synapse has enriched 10 related papers. Consider them for comparative context: